Beckman Coulter Diagnostics, a Danaher company, has launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. This new test is available for use on the DxI 9000 and Access 2 Immunoassay Analyzers.
BD-Tau is emerging as a highly promising blood-based biomarker for neurodegenerative research, offering enhanced specificity by detecting the short form of brain-derived tau directly in the blood. This minimizes confounding factors from peripheral tau sources, providing a more precise indicator of central nervous system pathology.
In related news, Beckman Coulter Diagnostics also announced the development of an Aβ-42 RUO immunoassay test for the same platforms. This development is a preparatory step for the IVD submission of its p-Tau 217/Aβ-42 ratio test, which has previously received Breakthrough Device Designation from the U.S. Food and Drug Administration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.